Genprex

Monthly Archives: December 2016

Genprex To Present at Biotech Showcase 2017

AUSTIN, TX, December 19, 2016 – Genprex, Inc. a biopharmaceutical company focused on the development of revolutionary immunogene therapy treatments, today announced that management will be presenting at Biotech Showcase 2017 to be held January 9-11, 2017 in San Francisco, concurrently with the J.P. Morgan Healthcare Conference, one of largest healthcare focused investor conferences in the U.S….

Read More

Genprex Retains ICR Healthcare as Integrated Strategic Communications Counsel

AUSTIN, TX, December 7, 2016 – Genprex, Inc. a biopharmaceutical company focused on the development of revolutionary immunogene therapy treatments, today announced that it has retained ICR Healthcare, a specialty healthcare practice within a leading strategic communications and advisory firm, to develop and implement an integrated strategic communications program. The program will combine investor relations, public relations and digital communications to advance the objective of raising the profile of Genprex and its lead candidate Oncoprex, which is currently in a Phase II trial for the treatment of non-small cell lung cancer (NSCLC)….

Read More